Published in Cell: TRON is part of a 36-member alliance led by the Parker Institute and Cancer Research Institute identifying parameters for better vaccine design in the fight against cancer. As part of TESLA (Tumor Neoantigen Selection Alliance), TRON performed advanced computational analysis on samples from melanoma and non-small cell lung cancer to identify characteristics
Archive | rechts News
Multi-omics characterization of the 4T1 murine mammary gland tumor model
The murine mammary carcinoma cell line 4T1 is a widely used syngeneic tumor model for human breast cancer and specifically triple-negative breast cancer (TNBC). Profiling tumor models is important to translate pre-clinical findings appropriately. The authors aimed to complement the evaluation of 4T1 as adequate breast cancer or even TNBC model. Analysis of the whole-exome
Dr. Luisa Bresadola awarded BMS Young Scientist prize
We are delighted to announce that TRON scientist Dr. Luisa Bresadola has won the Bristol-Myers-Squibb Young Scientist award in the field of immune-oncology! Luisa’s work comprises analysis of head and neck squamous cell carcinoma next-generation sequencing data, generated by TRON in collaboration with the University of Birmingham, to determine tumor evoluation in this cancer entity.
BioNTech IPO
TRON congratulates its cooperation Partner BioNTech SE on its successful IPO!
TRON scientists publish in Molecular Therapy
Mainz, September 27, 2019 – TRON scientists publish in Molecular Therapy TRON has published an article on a novel RNA-based vector for antigen delivery in Molecular Therapy. Among the exciting results, the authors show that trans-amplifying RNA as a vaccine vector induces protective immune responses against influenza challenge in mice, at a 400x lower dose
TRON scientists publish in Oncoimmunology
Mainz, July 19, 2019 – TRON scientists publish in Oncoimmunology TRON has published an article on the immunomodulatory effects of the TLR7 agonist SC1 in Oncoimmunology. Among the exciting results, the authors show that SC1 administration leads to inhibition of tumor growth and prolonged survival, and that this effect is dependent on CD8+ T cells.
TRON scientists are co-authors in a Nature Communications article
Mainz, December 6, 2018 – TRON scientists are co-authors in a Nature Communications article In collaboration with scientists from Italy and Germany, TRON has co-authored an article on the induction of immunosuppressive functions in monocytes by c-FLIP, published in Nature Communications. The data show that modulation of c-FLIP in monocytes may offer a path to
TRON Presented its Expertise in “Life Sciences”
TRON published an advertorial in the November 2018 issue of the Life Sciences magazine published by goingpublic.de. The advert featured TRON’s core competences and highlighted our leading edge research accomplishments. A PDF version of this article is available for download (German only).
Ugur Sahin co-authors Nature Reviews Drug Discovery article
Mainz, September 11, 2018 – TRON is thrilled to announce a review co-authored by Ugur Sahin in the journal Nature Reviews Drug Discovery. This article gives an over view of nascent RNA immunotherapeutics, including RNA vaccines encoding cancer neoantigens, mRNAs encoding immunomodulatory factors, viral RNA analogues, interference RNAs and protein-binding RNA aptamers. These approaches
TRON’s Mustafa Diken speaks at University Medical Center Frankfurt
Mainz, May 3, 2018 – The University Medical Center Frankfurt at Goethe University is hosting a seminar in the German Society for Immunology’s Translational Immunology Seminar Series. TRON’s Mustafa Diken will give a lecture titled “mRNA as a versatile platform for cancer vaccines” today at 3:00 p.m. in lecture hall B15 of Building 32 (entrance
Mustafa Diken speaks at the Institute for Chemical Immunology in Amsterdam
Mainz, March 16, 2018 – The Dutch Society for Immunology (NVVI) is hosting the 4th Chemical Immunology Conference today in Amsterdam. The meeting aims to cover the broad diversity of chemical immunology and some of the most exciting areas of research to have emerged. TRON’s Mustafa Diken kicks off the day with his plenary, “mRNA
Mini-Symposium – The Next Generation of Cancer Immunotherapy
Mainz, January 29, 2018 – The K. G. Jebsen Center for Cancer Immunotherapy is holding a mini-symposium on The Next Generation of Cancer Immunotherapy. In this context, on February 2 Prof. Ugur Sahin will give a lecture on Personalized Mutanome Vaccines.
